Krasimir A. Spasov

Yale University — United States

Medicine · Health Sciences

23h-index2.2kcitations46works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(26), HIV Research and Treatment(22), Pneumocystis jirovecii pneumonia detection and treatment(9), Biochemical and Molecular Research(7), Crystallization and Solubility Studies(5)

Publications46 total

Mechanistic basis for a novel dual-function Gag-Pol dimerizer potentiating CARD8 inflammasome activation and clearance of HIV-infected cells
npj Drug Discovery.·2025Open Access
Proof-of-concept studies with a computationally designed M<sup>pro</sup>inhibitor as a synergistic combination regimen alternative to Paxlovid
Proceedings of the National Academy of Sciences·2024· 15 citedOpen Access
Prodrug nanotherapy demonstrates <i>in vivo</i> anticryptosporidial efficacy in a mouse model of chronic <i>Cryptosporidium</i> infection
RSC Pharmaceutics·2024Open Access
Exploring novel <scp>HIV</scp>‐1 reverse transcriptase inhibitors with drug‐resistant mutants: A double mutant surprise
Protein Science·2023· 5 citedOpen Access
Covalent and noncovalent strategies for targeting Lys102 in HIV-1 reverse transcriptase
European Journal of Medicinal Chemistry·2023· 7 citedOpen Access
Design, synthesis, and biological testing of biphenylmethyloxazole inhibitors targeting HIV-1 reverse transcriptase
Bioorganic & Medicinal Chemistry Letters·2023· 5 citedOpen Access
Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase
Frontiers in Molecular Biosciences·2022· 10 citedOpen Access
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency
ACS Medicinal Chemistry Letters·2021· 55 citedOpen Access
Long‐acting and extended‐release implant and nanoformulations with a synergistic antiretroviral two‐drug combination controls <scp>HIV</scp>‐1 infection in a humanized mouse model
Bioengineering & Translational Medicine·2021· 12 citedOpen Access
Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations
ACS Central Science·2021· 253 citedOpen Access
Covalent Inhibition of Wild-Type HIV-1 Reverse Transcriptase Using a Fluorosulfate Warhead
ACS Medicinal Chemistry Letters·2021· 24 citedOpen Access
Structural investigation of <scp>2‐naphthyl</scp> phenyl ether inhibitors bound to <scp>WT</scp> and <scp>Y181C</scp> reverse transcriptase highlights key features of the <scp>NNRTI</scp> binding site
Protein Science·2020· 12 citedOpen Access
Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase
Bioorganic & Medicinal Chemistry Letters·2019· 7 citedOpen Access
Reply to Pandey et al.: Understanding the efficacy of a potential antiretroviral drug candidate in humanized mouse model of HIV infection
Proceedings of the National Academy of Sciences·2018Open Access
From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection
Proceedings of the National Academy of Sciences·2017· 36 citedOpen Access
Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography
Proceedings of the National Academy of Sciences·2017· 49 citedOpen Access
Design, Conformation, and Crystallography of 2-Naphthyl Phenyl Ethers as Potent Anti-HIV Agents
ACS Medicinal Chemistry Letters·2016· 27 citedOpen Access
Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance
ACS Medicinal Chemistry Letters·2015· 26 citedOpen Access
Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase
Bioorganic & Medicinal Chemistry Letters·2015· 20 citedOpen Access
Structure-Based Evaluation of Non-nucleoside Inhibitors with Improved Potency and Solubility That Target HIV Reverse Transcriptase Variants
Journal of Medicinal Chemistry·2015· 47 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Karen S. Anderson(37), William L. Jorgensen(31), Mariela Bollini(12), Kathleen M. Frey(11), Robert A. Domaoal(11), Won‐Gil Lee(8), Joseph A. Ippolito(6), Ricardo Gallardo‐Macias(6), Alpay Dermenci(6), Philipp Selig(6), Albert H. Chan(6), José A. Cisneros(6), Shalley N. Kudalkar(5), Klarissa Hollander(5), S.J. Miller(5), Vinzenz M. Unger(4), Priti Kumar(4), Julian Tirado‐Rives(3), Brett D. Lindenbach(3), Scott J. Miller(3)